Giessen Pulmonary Hypertension in Lung Cancer Registry
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: All lung cancer patients..
- Who it may be relevant to
- Registry conditions: Pulmonary Hypertension Due to Lung Diseases and Hypoxia. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Germany
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
The aim of this study is to investigate the frequency and implications of pulmonary hypertension in lung cancer patients. To do so, data will be collected from all lung cancer patients at the university hospital Giessen. All data will be analyzed for possible hints of pulmonary hypertension as a comorbidity in lung cancer patients. All information will be generated from the regular guidelines based course of treatment and there will be no interventions. This study will serve as a prospective register for all lung cancer patients treated at the university hospital Giessen.
Interventions
- Other All lung cancer patients.
There will be no specific interventions. All patients will receive guidelines based therapy of lung cancer and their comorbidities.
Primary outcome measures
- Pulmonary function test measured via Spirometry. [Time frame: 2 years]
- sPAP values measured via Echocardiography. [Time frame: 2 years]
- Body mass index. [Time frame: 2 years]
- Overall Survival and Progression Free Survival measured in days. [Time frame: 2 years]
- Measurements of the pulmonary artery diameter (PA) and ascending aorta (AA) diameter measured via computed tomography scan. PA and AA will be measured in millimeters. [Time frame: 2 years]
- 6 Minute Walk Test in meters. [Time frame: 2 years]
- Modified Medical Research Council Scale (mMRC). [Time frame: 2 years]
- chronic obstructive pulmonary disease assessment test (CAT). [Time frame: 2 years]
Eligibility criteria
Inclusion criteria
- Patient with lung cancer at the University of Giessen lung Cancer Center.
Exclusion criteria
\-
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Germany · 1 center
- University hospital Giessen — Giessen
Publications
- Pullamsetti SS, Kojonazarov B, Storn S, Gall H, Salazar Y, Wolf J, Weigert A, El-Nikhely N, Ghofrani HA, Krombach GA, Fink L, Gattenlohner S, Rapp UR, Schermuly RT, Grimminger F, Seeger W, Savai R. Lung cancer-associated pulmonary hypertension: Role of microenvironmental inflammation based on tumor cell-immune cell cross-talk. Sci Transl Med. 2017 Nov 15;9(416):eaai9048. doi: 10.1126/scitranslmed. PMID 29141888
- Rako ZA, Cekay M, Yogeswaran A, Yildiz S, Arndt PF, Kremer N, Schafer S, Janetzko P, Thal BR, Mummert CM, Franken JK, Soethe H, Werner HF, Dumitrascu R, Grimminger F, Ghofrani HA, Pullamsetti SS, Seeger W, Naeije R, Savai R, Eul B, Tello K. Echocardiographic Measure of Right Ventricular-Pulmonary Arterial Coupling Predicts Survival in Lung Cancer. Ann Am Thorac Soc. 2025 Jul;22(7):1071-1078. doi: PMID 40042816
Identifiers
NCT: NCT04467333 · PH in lung cancer registry